Evidence map›Paper›PMID 25815175›Full record

ArticleClinical kidney journal2015

Treatment of adynamic bone disease in a haemodialysis patient with teriparatide.

Panagiotis Giamalis, Dominiki Economidou, Chrysostomos Dimitriadis, Dimitrios Memmos, Aikaterini Papagianni, Georgios Efstratiadis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.International journal of molecular sciences · 2020
    Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Management of adynamic bone disease in chronic kidney disease: A brief review.Journal of clinical & translational endocrinology · 2016
    Review
  13. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Observational
  14. Adynamic bone disease.Jornal brasileiro de nefrologia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Panagiotis GiamalisDepartment of Nephrology, Aristotle University of Thessaloniki , Hippokration General Hospital , Thessaloniki , Greece.
Dominiki EconomidouDepartment of Nephrology, Aristotle University of Thessaloniki , Hippokration General Hospital , Thessaloniki , Greece.
Chrysostomos DimitriadisDepartment of Nephrology, Aristotle University of Thessaloniki , Hippokration General Hospital , Thessaloniki , Greece.
Dimitrios MemmosDepartment of Nephrology, Aristotle University of Thessaloniki , Hippokration General Hospital , Thessaloniki , Greece.
Aikaterini PapagianniDepartment of Nephrology, Aristotle University of Thessaloniki , Hippokration General Hospital , Thessaloniki , Greece.
Georgios EfstratiadisDepartment of Nephrology, Aristotle University of Thessaloniki , Hippokration General Hospital , Thessaloniki , Greece.
Aristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevalence of adynamic bone disease (ABD), characterized by low bone turnover and absence or a reduced number of osteoblasts and osteoclasts, is increasing steadily over the last years. We present a dialysis patient, with recurrent bone fractures and biopsy-proven ABD, who was treated with teriparatide. Nine months after initiation of treatment, iPTH plasma levels increased to 520 pg/mL and a second bone biopsy revealed high bone turnover, normal mineralization and normal bone volume. Two years later, iPTH was 250-350 pg/dL and bone metabolism parameters within normal range. The probable utility of teriparatide in the treatment of ABD in dialysis patients is discussed.

Indexed as

adynamic bone diseasehaemodialysisteriparatide

Identifiers

PMID25815175
PMCPMC4370305
OpenAlexW2171983194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.